PENNSAID

Peak

diclofenac sodium

Amgen

NDATOPICALSOLUTION

Approved

Jan 2014

Lifecycle

Peak

Competitive Pressure

8/100

Clinical Trials

Data completeness

5/8 — Partial

PENNSAID (diclofenac sodium) by Amgen is (ak) is unknown. Approved for pain, osteoarthritis, low back pain and 4 more indications. First approved in 2014.

Drug data last refreshed 20h ago

Mechanism of Action

(AK) is unknown.

Indications (7)

Pain(5)Osteoarthritis(4)Low Back Pain

Worked on PENNSAID at Amgen? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT05387525Phase 4Active Not Recruiting

A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

Started Oct 2022

447 enrolled

Keratosis, Actinic

NCT02985671Phase 3Unknown

To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.

Started Jan 2021

110 enrolled

Postural Low Back PainMechanical Low Back Pain

NCT02611804Phase 3Completed

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

Started Oct 2015

492 enrolled

Actinic Keratosis

NCT02406014Phase 4Completed

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Started Apr 2015

502 enrolled

Actinic Keratosis (AK)

NCT02290821Phase 3Completed

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries

Started Dec 2014

215 enrolled

Acute Blunt Soft Tissue Injuries/Contusions

PENNSAID

Mechanism of Action

Indications (7)

Clinical Trials (20)

Why This Matters for Your Career